Influence of pharmaceutical factors on the dissolution profile of granules for oral suspension with nimesulide
In vitro dissolution profiles are investigated to predict the behavior of the drug in the body and to establish its effectiveness. The choice of medium and dissolution conditions depends on the class of BSC of the active substance or substances that are part of the drug. In this work, nimesulide was chosen as a model substance, which is a sparingly soluble substance of class II BSC, when bioavailability is limited only by dissolution.
The aim of the work was to establish optimal conditions for determining the dissolution profiles of Nimesulide, granules for oral solution, 100 mg/2 g and to study the effect of compositional variables on the release of API.
The subject of the study was granules for oral suspension, made on the basis of nimesulide. In the experiment used the substance nimesulide 3 manufacturers, corn starch and macrogol 20 (polyethylene glycol) cetostearyl ether. The particle size of the substances was investigated by laser diffraction. Determination of nimesulide release was performed by HPLC.
The results of the study of the dissolution profiles of the drug Aulin, granules for oral suspension in pH 6.8, 7.5 and 7.8, where the active substance is not completely released. The addition of surfactants was used to increase the solubility of the drug. It has been experimentally confirmed that when using API nimesulide with a particle size D (90) = 64 μm, the release profiles are below the comparison drug. The similarity of the dissolution profiles of the test agent and the comparison drug provide API with a particle size D (90) < 30 μm. The dependence of the dissolution profile on the amounts of corn starch and macrogol 20 (polyethylene glycol) of cetostearyl ether is given, their optimal content in the composition of the drug is established.
In the result of the work, the influence of research conditions on the dissolution profile of Aulin, granules for oral suspension, 100 mg/2 g was studied. pH 6.8 + 1% tween 80 and pH 7.4 + 0.5% tween 80 were chosen as optimal media. Experiments showed that the particle size of API nimesulide D (90) < 30 μm ensures compliance with the drug Nimesulide, granules for oral suspension, 100 mg/2 g by dissolution profiles. Increasing the amount of corn starch in the composition of the drug accelerates the dissolution of the granules and, as a consequence, raises the first points of the release profile of API. The use of 0.5% corn starch provides the dissolution profile closest to the comparison drug. To completely release API as a solubilizer, it is advisable to add 1% macrogol 20 (polyethylene glycol) cetostearyl ether.
Muselík J., Komersová A., Kubová K. et al. A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products // Pharmaceutics. – 2021. – V. 13, Iss. 10. – P. 1703–1715. https://doi.org/10.3390/pharmaceutics13101703
Hoffelder T. Comparison of Dissolution Profiles: A Statistician’s Perspective // Therapeutic innovation & regulatory science. – 2018. – V. 52, Iss. 4. – P. 423–429. https://doi.org/10.1177/2168479017749230
Siew A. Understanding Dissolution Testing // Pharmac. Technol. – 2017. – V. 41, Iss. 6. – P. 48–52.
Nastanova Likarsʹki zasoby: doslidzhennya bioekvivalentnosti. Ct-n MOZ Ukrayiny 42-7.3:2020 / Ministerstvo okhorony zdorovʹya Ukrayiny. – Kyiv, 2020. – 86 s.
Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action: EMA/CHMP/CVMP/QWP/336031/2017 / Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP), 2017. – 10 р.
Gray V. A. Power of the Dissolution Test in Distinguishing a Change in Dosage Form Critical Quality Attributes // AAPS Pharm. Sc. Tech. – 2018. – V. 19, Iss. 8. – P. 3328–3332. https://doi.org/10.1208/s12249-018-1197-7
Flanagan T., Mann J. Dissolution Universal Strategy Tool (DUST): A Tool to Guide Dissolution Method Development Strategy // Dissolution Technologies. – 2019. – V. 26, Iss. 3. – P. 6–17. https://doi.org/10.14227/DT260319P6
Guidelines on the investigation of bioequivalence: CPMP/EWP/QWP/1401/98 Rev. 1. European Medicines Agency, 2010. – 27 p.
Committee for Medicinal Products for Human Use ICH M9 guideline on biopharmaceutics classification system-based biowaivers: EMA/CHMP/ICH/493213/2018. European Medicines Agency, 2020. – 22 p.
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances: Guidance for Industry / U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2018.
Simionato L. D., Petrone L., Baldut M. et al. Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina // Saudi Рharmacy. J. (SPJ). – 2018. – V. 26, Iss. 4. – P. 578–584. https://doi.org/10.1016/j.jsps.2018.01.015
Hanif M., Shoaib M. H., Yousuf R. I. et al. Development of in vitro – in vivo correlations for newly optimized Nimesulide formulations // Plos. Оne. – 2018. – V. 13, Iss. 8. – P. 1–11. https://doi.org/10.1371/journal.pone.0203123
Kolla S. B., Vallabhaneni M. R., Puttagunta S. B. et al. Design of Experiments Approach to Discriminatory Dissolution Method Development of Poorly Soluble Drug in Immediate Release Dosage Form // Indian J. Pharmac. Educ. Res. – 2019. – V. 53, Iss. 3. – P. 435–445.
Pikhlak A. E. Efficacy and Safety of Nimesulide in the Complex Treatment of Patients with Knee and Hip Osteoarthritis // EC Orthopaedics. – 2018. – V. 9. – P. 12–18.
Zazirnyy I. M. Efektyvnistʹ zastosuvannya preparatu Nimedar v ortopedychniy praktytsi // Travma. – 2018. – Vyp. 19, № 2. – S. 29–35.
Ola M., Bhaskar R., Patil P. Dry syrup: An overview // Indian J. Pharmac. Biol. Res. – 2018. – V. 6, Iss. 03. – P. 30–38. https://doi.org/10.30750/ijpbr.6.3.5
Vinarov Z., Katev V., Radeva D. et al. Micellar solubilization of poorly water-soluble drugs: effect of surfactant and solubilizate molecular structure // Drug Development and Industrial Pharmacy. – 2018. – V. 44, N 4. – P. 677–686. https://doi.org/10.1080/03639045.2017.1408642
Bou-Chacra N., Melo K. J. C., Morales I. A. C. et al. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System // The AAPS J. – 2017. – V. 19. – P. 989–1001. https://doi.org/10.1208/s12248-017-0085-5
Derzhavna farmakopeya Ukrayiny: T. 1 / DР «Ukrayinsʹkyy naukovyy farmakopeynyy tsentr yakosti likarsʹkykh zasobiv». – Kharkiv: DР «Ukrayinsʹkyy naukovyy farmakopeynyy tsentr yakosti likarsʹkykh zasobiv», 2015. – 1130 s.
European Pharmacopoeia current hot topics / European Directorate for the Quality of Medicines and Health Care (EDQM). – Strasbourg: Council of Europe, 2016. – 21 p.
This work is licensed under a Creative Commons Attribution 4.0 International License.